Search alternatives:
largest decrease » largest decreases (Expand Search), marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
largest decrease » largest decreases (Expand Search), marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
8841
Table 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). …”
-
8842
Image 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). …”
-
8843
Table 7_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). …”
-
8844
Table 8_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). …”
-
8845
Table 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). …”
-
8846
Image 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). …”
-
8847
Table 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). …”
-
8848
Table 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). …”
-
8849
Table 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). …”
-
8850
Image 1_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). …”
-
8851
Image 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). …”
-
8852
Table 1_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). …”
-
8853
Image 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). …”
-
8854
DataSheet_1_Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide...
Published 2022“…The 20.2% of the mean PRNT titer of convalescent sera was used as 50% protective value, and the percentage of HCWs with protective immunity for each week (percent-week) was compared among vaccination groups. A correlation equation was deduced between a PRNT 50% neutralizing dose (ND<sub>50</sub>) against wild type (WT) SARS-CoV-2 and that of the Delta variant.…”
-
8855
Performance of PAV adjusted model sets vs unadjusted model sets in INTERVAL.
Published 2022“…Most models are either unadjusted (yellow) or have only a small decrease in performance. 7.0% of models had a larger decrease in performance (change in <i>ρ</i> > 0.1), but maintained significance. …”
-
8856
AUROC as a function of inspired N<sub>2</sub>O concentration for the 60% peak gas group for (top left) weighted global efficiency, , (top right) global coherence, , at 11 Hz, (bott...
Published 2013“…The difference in the median measure value relative to rest is indicated by the the direction of the respective bar (up, increase; down, decrease). Gray shading indicates ROC curve areas signifying a chance or worse ability to discriminate between randomly chosen gas and rest measures. …”
-
8857
Views of the branchial basket flow chambers and cartilage skeleton in a mature, NF 58 larva.
Published 2023“…The ornate processes decrease in size dorsally and the largest, near the ceratobranchial bases, form a meshwork above each gill slit (small arrows in d). …”
-
8858
Exploration of Sweeping Effect: Droplet Coalescence Jumping of a Rolling and Static Droplet
Published 2024“…In this work, we experimentally and numerically study the coalescence of a rolling droplet and a static one. When the droplet radius ratio is larger than 0.8, as the dimensionless initial velocity increases and the vertical jumping velocity first decreases and then increases. …”
-
8859
datasheet1_Piperazine-Derived α1D/1A Antagonist 1- Benzyl-N- (3-(4- (2-Methoxyphenyl) Piperazine-1-yl) Propyl) -1H- Indole-2- Carboxamide Induces Apoptosis in Benign Prostatic Hype...
Published 2021“…<p>Previous studies have indicated that α<sub>1D/1A</sub> antagonist naftopidil (NAF) suppresses prostate growth by decreasing cell proliferation without affecting apoptosis and prostate volume in benign prostatic hyperplasia (BPH). …”
-
8860
The presence of the spatial positive feedback allows for efficient inhibition.
Published 2022“…The decrease in pVav1 Model 2 is more pronounced at larger HLA-C concentrations when HLA-C are organized in a ring pattern (C) vs distributed homogeneously (D). …”